Alzheimer’s Drug Discovery Foundation – Drug Development RFP
Ends on 15 September 2025
The Drug Development RFP supports investigational new drug (IND)-enabling studies (or the international equivalent) and early-phase clinical trials that test promising pharmacological interventions and devices for Alzheimer’s disease (AD) and related dementias. This funding opportunity concentrates on diverse drug mechanisms and modes of action related to the biology of aging and other emerging therapeutic areas for dementia.
ADDF strategic priorities include: Combination therapies of two or more drugs to be administered together or development of combination products or Disease-modifying and symptomatic agents.